Shareholders Foundation, Inc.

NASDAQ:OCUL Investor Alert: Lawsuit Alleges Securities Laws Violations by Ocular Therapeutix Inc

A lawsuit was filed on behalf of investors in Ocular Therapeutix Inc (NASDAQ:OCUL) shares over alleged securities laws violations.

 

San Diego, CA -- (SBWIRE) -- 08/16/2017 -- An investor in NASDAQ:OCUL shares filed a lawsuit against Ocular Therapeutix Inc over alleged Securities Laws violations.

Investors who purchased shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have certain options and for certain investors are short and strict deadlines running. Deadline: September 5, 2017. NASDAQ:OCUL investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint the plaintiff alleges on behalf of purchasers of Ocular Therapeutix Inc (NASDAQ:OCUL) common shares between May 5, 2017 and July 6, 2017, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 5, 2017 and July 6, 2017 Ocular Therapeutix issued false and/or misleading statements and/or failed to disclose that Ocular Therapeutix's management has been misleading investors about DEXTENZA manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix contain bad product that such manufacturing issues could imperil the approval of DEXTENZA by the FDA, and that as a result, defendants' public statements were materially false and misleading at all relevant times.

Bedford, MA based Ocular Therapeutix, Inc. is a biopharmaceutical company that is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. On May 5, 2017, Ocular Therapeutix Inc disclosed that the U.S. Food and Drug Administration ("FDA") had found minor issues at its manufacturing plant, but downplayed any concerns.

On July 6, 2017, an article was published asserting that Ocular Therapeutix's management has been misleading investors about manufacturing issues, including that more than 50% of lots manufactured by Ocular Therapeutix Inc contain bad product.

Those who purchased shares of Ocular Therapeutix Inc (NASDAQ:OCUL) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com